Hosted on MSN28d
FDA extends review of Fortress Biotech's CUTX-101 drugannounced today that the U.S. Food and Drug Administration (FDA) has extended the target action date for the New Drug Application (NDA) of CUTX-101, Copper Histidinate, to September 30 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback